基石药业(02616.HK)治疗多种实体瘤产品CS2009在澳洲递交临床试验申请

阿斯达克财经
23 Dec 2024

基石药业(02616.HK) 公布,其用于治疗多种实体瘤的管线2.0重磅产品CS2009 (PD-1/VEGF/CTLA-4三特异性抗体)已在澳洲递交临床试验申请。

CS2009具有明显优于潜在竞品的抗肿瘤活性,有望覆盖广泛瘤种,包括非小细胞肺癌,卵巢癌,肾细胞癌,宫颈癌,肝癌,胃癌等,成为同类首创/同类最优的下一代肿瘤免疫骨架产品。(jl/w)(港股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10